PURPOSE: To develop and apply a semiautomatic method of segmenting fibroglandular tissue to quantify magnetic resonance (MR) imaging contrast material-enhancement kinetics of breast background parenchyma (BP) and lesions throughout the phases of the menstrual cycle in women with benign and malignant lesions. MATERIALS AND METHODS: The institutional review board approved this retrospective HIPAA-compliant study, and informed consent was waived. From December 2008 to August 2011, 58 premenopausal women who had undergone contrast material-enhanced MR imaging and MR imaging-guided biopsy were identified. The longest time from the start of the last known period was 34 days. One lesion per patient (37 benign and 21 malignant) was analyzed. The patient groups were stratified according to the week of the menstrual cycle when MR imaging was performed. A method based on principal component analysis (PCA) was applied for quantitative analysis of signal enhancement in the BP and lesions by using the percentage of slope and percentage of enhancement. Linear regression and the Mann-Whitney U test were used to assess the association between the kinetic parameters and the week of the menstrual cycle. RESULTS: In the women with benign lesions, percentages of slope and enhancement for both BP and lesions during week 2 were significantly (P < .05) lower than those in week 4. Percentage of enhancement in the lesion in week 2 was lower than that in week 3 (P < .05). The MR images of women with malignant lesions showed no significant difference between the weeks for any of the parameters. There was a strong positive correlation between lesion and BP percentage of slope (r = 0.72) and between lesion and BP percentage of enhancement (r = 0.67) in the benign group. There was also a significant (P = .03) difference in lesion percentage of slope between the benign and malignant groups at week 2. CONCLUSION: The PCA-based method can quantify contrast enhancement kinetics of BP semiautomatically, and kinetics of BP and lesions vary according to the week of the menstrual cycle in benign but not in malignant lesions.
PURPOSE: To develop and apply a semiautomatic method of segmenting fibroglandular tissue to quantify magnetic resonance (MR) imaging contrast material-enhancement kinetics of breast background parenchyma (BP) and lesions throughout the phases of the menstrual cycle in women with benign and malignant lesions. MATERIALS AND METHODS: The institutional review board approved this retrospective HIPAA-compliant study, and informed consent was waived. From December 2008 to August 2011, 58 premenopausal women who had undergone contrast material-enhanced MR imaging and MR imaging-guided biopsy were identified. The longest time from the start of the last known period was 34 days. One lesion per patient (37 benign and 21 malignant) was analyzed. The patient groups were stratified according to the week of the menstrual cycle when MR imaging was performed. A method based on principal component analysis (PCA) was applied for quantitative analysis of signal enhancement in the BP and lesions by using the percentage of slope and percentage of enhancement. Linear regression and the Mann-Whitney U test were used to assess the association between the kinetic parameters and the week of the menstrual cycle. RESULTS: In the women with benign lesions, percentages of slope and enhancement for both BP and lesions during week 2 were significantly (P < .05) lower than those in week 4. Percentage of enhancement in the lesion in week 2 was lower than that in week 3 (P < .05). The MR images of women with malignant lesions showed no significant difference between the weeks for any of the parameters. There was a strong positive correlation between lesion and BP percentage of slope (r = 0.72) and between lesion and BP percentage of enhancement (r = 0.67) in the benign group. There was also a significant (P = .03) difference in lesion percentage of slope between the benign and malignant groups at week 2. CONCLUSION: The PCA-based method can quantify contrast enhancement kinetics of BP semiautomatically, and kinetics of BP and lesions vary according to the week of the menstrual cycle in benign but not in malignant lesions.
Authors: Niamh M Hambly; Laura Liberman; D David Dershaw; Sandra Brennan; Elizabeth A Morris Journal: AJR Am J Roentgenol Date: 2011-01 Impact factor: 3.959
Authors: Riham H El Khouli; Katarzyna J Macura; Michael A Jacobs; Tarek H Khalil; Ihab R Kamel; Andrew Dwyer; David A Bluemke Journal: AJR Am J Roentgenol Date: 2009-10 Impact factor: 3.959
Authors: Sungheon Kim; Harry Quon; Laurie A Loevner; Mark A Rosen; Lawrence Dougherty; Alex M Kilger; Jerry D Glickson; Harish Poptani Journal: J Magn Reson Imaging Date: 2007-12 Impact factor: 4.813
Authors: Doris Leithner; Thomas H Helbich; Blanca Bernard-Davila; Maria Adele Marino; Daly Avendano; Danny F Martinez; Maxine S Jochelson; Panagiotis Kapetas; Pascal A T Baltzer; Alexander Haug; Marcus Hacker; Yasemin Tanyildizi; Elizabeth A Morris; Katja Pinker Journal: J Nucl Med Date: 2019-06-28 Impact factor: 10.057
Authors: Alana A Lewin; Sungheon Gene Kim; James S Babb; Amy N Melsaether; Jason McKellop; Melanie Moccaldi; Ana Paula Klautau Leite; Linda Moy Journal: Acad Radiol Date: 2016-01-07 Impact factor: 3.173
Authors: Shandong Wu; Susan P Weinstein; Michael J DeLeo; Emily F Conant; Jinbo Chen; Susan M Domchek; Despina Kontos Journal: Breast Cancer Res Date: 2015-05-19 Impact factor: 6.466